BioSpace News Archive

NKGen Biotech, Inc. announced that it has closed $5 million in second lien convertible loan funding with a term of 30 months, augmenting approximately $4.75 in gross cash proceeds from prior 2024 funding to date.

Tevogen Bio Holdings, is a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.

Prime Therapeutics LLC / Magellan Rx Management, LLC continues to publish award-winning and industry-leading research on a range of clinical topics impacting the health care and pharmacy benefit management industry. Thought leaders from Prime/MRx will present eight research studies at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting, April 15-18 in New Orleans.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2024 financial results and provide an update on the company’s business and outlook on Thursday, April 25 , at 4:30 p.m. ET.

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, May 13, 2024, to review first-quarter 2024 results.

Aptevo Therapeutics Inc. today announced the pricing of a public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock.

SciSparc Ltd. announced today that it signed a merger agreement (the “Agreement”) with AutoMax Motors Ltd. (“AutoMax”), a leading vehicle importer company in Israel.

Nectero Medical today announced the closing of its $96 million Series D financing round.

Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announces the launch of xeo+, a pioneering laser and light-based multi-application platform built on a rich history of excellence in performance and innovation.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology AI.